A clinical study in a small SCD cohort (n = 26) demonstrated that short-term simvastatin administration significantly improved nitric oxide bioavailability by approximately 52% (p = 0.01) and suppressed systemic inflammatory biomarkers such as CRP and IL-6, both of which are associated with increased vascular dysfunction risks in SCD (Hoppe et al., 2011). Here, CRP is linked to Schnyder corneal dystrophy.